Compare MNDO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNDO | GDTC |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | Israel | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 24.8M |
| IPO Year | 2000 | 2023 |
| Metric | MNDO | GDTC |
|---|---|---|
| Price | $1.23 | $1.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.3K | ★ 135.8K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | ★ 17.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $19,770,000.00 | $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.71 | ★ N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $0.98 | $1.65 |
| 52 Week High | $2.13 | $4.05 |
| Indicator | MNDO | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 40.07 |
| Support Level | $1.18 | $1.72 |
| Resistance Level | $1.22 | $1.88 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 90.00 | 10.33 |
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.